TY - JOUR
T1 - The potential of the mevalonate pathway for enhanced isoprenoid production
AU - Liao, Pan
AU - Hemmerlin, Andréa
AU - Bach, Thomas J.
AU - Chye, Mee Len
N1 - Funding Information:
This work was supported by the Wilson and Amelia Wong Endowment Fund, Research Grants Council of Hong Kong (AoE/M-05/12) and the University of Hong Kong (Postdoctoral Fellowship to PL).
Funding Information:
This work was supported by the Wilson and Amelia Wong Endowment Fund , Research Grants Council of Hong Kong ( AoE/M-05/12 ) and the University of Hong Kong (Postdoctoral Fellowship to PL).
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/9
Y1 - 2016/9
N2 - The cytosol-localised mevalonic acid (MVA) pathway delivers the basic isoprene unit isopentenyl diphosphate (IPP). In higher plants, this central metabolic intermediate is also synthesised by the plastid-localised methylerythritol phosphate (MEP) pathway. Both MVA and MEP pathways conspire through exchange of intermediates and regulatory interactions. Products downstream of IPP such as phytosterols, carotenoids, vitamin E, artemisinin, tanshinone and paclitaxel demonstrate antioxidant, cholesterol-reducing, anti-ageing, anticancer, antimalarial, anti-inflammatory and antibacterial activities. Other isoprenoid precursors including isoprene, isoprenol, geraniol, farnesene and farnesol are economically valuable. An update on the MVA pathway and its interaction with the MEP pathway is presented, including the improvement in the production of phytosterols and other isoprenoid derivatives. Such attempts are for instance based on the bioengineering of microbes such as Escherichia coli and Saccharomyces cerevisiae, as well as plants. The function of relevant genes in the MVA pathway that can be utilised in metabolic engineering is reviewed and future perspectives are presented.
AB - The cytosol-localised mevalonic acid (MVA) pathway delivers the basic isoprene unit isopentenyl diphosphate (IPP). In higher plants, this central metabolic intermediate is also synthesised by the plastid-localised methylerythritol phosphate (MEP) pathway. Both MVA and MEP pathways conspire through exchange of intermediates and regulatory interactions. Products downstream of IPP such as phytosterols, carotenoids, vitamin E, artemisinin, tanshinone and paclitaxel demonstrate antioxidant, cholesterol-reducing, anti-ageing, anticancer, antimalarial, anti-inflammatory and antibacterial activities. Other isoprenoid precursors including isoprene, isoprenol, geraniol, farnesene and farnesol are economically valuable. An update on the MVA pathway and its interaction with the MEP pathway is presented, including the improvement in the production of phytosterols and other isoprenoid derivatives. Such attempts are for instance based on the bioengineering of microbes such as Escherichia coli and Saccharomyces cerevisiae, as well as plants. The function of relevant genes in the MVA pathway that can be utilised in metabolic engineering is reviewed and future perspectives are presented.
KW - Escherichia coli
KW - HMGR
KW - HMGS
KW - Isoprenoids
KW - Mevalonate
KW - MVA pathway
KW - Plants
KW - Saccharomyces cerevisiae
UR - http://www.scopus.com/inward/record.url?scp=84963516460&partnerID=8YFLogxK
U2 - 10.1016/j.biotechadv.2016.03.005
DO - 10.1016/j.biotechadv.2016.03.005
M3 - Review article
C2 - 26995109
AN - SCOPUS:84963516460
SN - 0734-9750
VL - 34
SP - 697
EP - 713
JO - Biotechnology Advances
JF - Biotechnology Advances
IS - 5
ER -
